YNHH HOME    |    OUR DOCTORS    |    EMPLOYMENT    |    DIRECTIONS    |    QUALITY    |    CONTACT US

Yale discovery may lead to drug that cuts appetite, boosts energy

Yale University Press Release
Office of Public Affairs
Release Date:
July 20, 2009
Media contact:
Karen N. Peart
karen.peart@yale.edu
203-432-1326

In a major advance in obesity and diabetes research, Yale School of Medicine scientists have found that reducing levels of a key enzyme in the brain decreased appetites and increased energy levels.

Reductions in the levels of the enzyme prolylcarboxypeptidase (PRCP) led to weight loss and a decreased risk of type 2 diabetes in mice, according to research published in the August issue of The Journal of Clinical Investigation. The team found that PRCP is located in the hypothalamus and regulates levels of a peptide known for inhibiting food intake and stimulating energy expenditure — the alpha-melanocyte stimulating hormone (alpha-MSH). Researchers found that blocking the PRCP enzyme keeps the alpha-MSH peptides from being degraded, resulting in higher levels of alpha-MSH and decreased appetite.

"Our research provides the first evidence that breaking down molecules in the brain that regulate metabolism is an important component of weight control," said senior author Sabrina Diano, associate professor in the Departments of Obstetrics, Gynecology and Reproductive Sciences, and Neurobiology. "Our findings provide a possible new target for the development of drugs to control metabolic disorders such as obesity and type 2 diabetes."

Diano and her team conducted the study in congenic mice that were naturally lean and later in mice that had PRCP removed. Animals without the PRCP enzyme were leaner and ate less food. They also had higher levels of alpha-MSH in the hypothalamus compared to control animals. The mice were put on a diet of 45 percent fat—the equivalent of eating fast food everyday—and even with this high fat diet, they did not gain as much weight as control animals on a regular diet.

Diano said the next step is to study how PRCP is regulated.

Other authors on the study include Nicholas Wallingford, Bertrand Perroud, Qian Gao, Anna Coppola, Erika Gyengesi, Zhong-Wu-Liu, Xiao-Bing Gao, Adam Diament, Kari A. Haus, Zia Shariat-Madar, Fakhri Mahdi, Sharon L. Wardlaw, Alvin H. Schmaier and Craig H. Warden.

The Journal of Clinical Investigation, Vol. 119, No. 8 (August 2009)



Established in 1810, the Yale School of Medicine is known throughout the world as one of the leading centers for biomedical research, education and advanced health care. Founded in 1810, the School of Medicine has grown to include every modern medical discipline. Its faculty includes some of the world's most respected scholars in medicine, public health and biomedical science. http://info.med.yale.edu/ysm/

Revised January 27, 2010 by dh By accessing this Website, you agree to be bound by the terms and conditions set forth in our Privacy Policy, Usage Policy and other disclaimer pages and any other terms concerning use and operation of this site. All information is intended for your general knowledge and is not a substitute for medical advice or treatment for specific medical conditions. You should seek prompt medical care for any specific health issues and consult your physician before starting a new fitness regimen. Copyright © 2010, Yale-New Haven Hospital. All rights reserved. Comments or suggestions to the site editor.